-transparent.png){kind=logo}
This study was undertaken to examine the elimination of orally administered acebutolol and its major acetyl metabolite in four healthy controls and seven patients with varying degrees of renal functional impairment. Analysis of acebutolol and its metabolites was undertaken using a high performance liquid chromatographic method. Plasma concentrations of acebutolol and the acetyl metabolite were greater in patients with renal functional impairment than in controls. The elimination of acebutolol did not appear to be influenced by impaired renal function. However the elimination of the acetyl metabolite decreased as renal function diminished. Acebutolol has a major non-renal route of elimination, but the acetyl metabolite (also a beta-adrenoreceptor blocking drug) is primarily excreted by the kidney and may accumulate in renal failure.
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
August 1982,
Clinical nephrology,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
June 1981,
The Journal of pharmacy and pharmacology,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
October 1974,
Journal of clinical pharmacology,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
January 1988,
Journal of inherited metabolic disease,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
October 1995,
Therapeutic drug monitoring,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
September 1976,
Research communications in chemical pathology and pharmacology,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
October 1981,
British journal of clinical pharmacology,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
April 2004,
British journal of anaesthesia,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
October 1998,
Psychiatry and clinical neurosciences,
S Munn, and
R R Bailey, and
E Begg, and
R Ebert, and
D G Ferry
October 1977,
British journal of clinical pharmacology,
